Testing ABBV-383 for returning Waldenström macroglobulinemia
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug, ABBV-383, for people with Waldenström macroglobulinemia that has come back or not responded to prior treatment. It aims to see if this drug can help when other treatments, like BTK inhibitors, have already been tried.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have Waldenström macroglobulinemia that has returned or not responded to treatment, and you have tried a BTK inhibitor (unless it wasn't safe for you).
- Your IgM levels are at least 0.5 g/dL (500 mg/dL).
- You are able to care for yourself (ECOG performance status 0, 1, or 2).
- You have not been treated with ABBV-383 or similar drugs before.
- Your blood counts (hemoglobin, neutrophils, platelets) meet specific minimum levels within the last 14 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and rituximab) for people newly diagnosed with Waldenstrom's macroglobulinemia who have not had treatment before and need therapy for their symptoms.
This trial tests a combination of three drugs (zanubrutinib, bendamustine, and rituximab) for people with Waldenstrom macroglobulinemia who have not been treated before. The goal is to see if this combination is safe and effective.
This trial tests a combination of two targeted drugs, zanubrutinib and BGB-11417, for people with Waldenström Macroglobulinemia who have already had at least one prior treatment. The goal is to see if this two-drug approach works better than standard options.
This trial tests epcoritamab, an immunotherapy that helps your immune system attack cancer cells, for people with Waldenstrom macroglobulinemia (WM) whose disease has gotten worse or who couldn't tolerate previous treatments. It's for those who've already tried a BTK inhibitor (like ibrutinib or zanubrutinib) and an anti-CD20 antibody (like rituximab).
This trial tests a combination of two drugs—mosunetuzumab and pirtobrutinib—in patients whose Waldenstrom macroglobulinemia (a rare blood cancer) has returned or stopped responding to prior treatment. The study aims to see if this combination can shrink tumors and help patients feel better.
This trial tests a new pill (zanubrutinib) combined with a short course of antibody therapy and a lower dose of chemo for people with Waldenström's macroglobulinemia who haven't had strong treatment before. The goal is to see if this gentler combination can control the disease well.
Hear when a new Recurrent Waldenstrom Macroglobulinemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.